Monday December 8, 2014
Radisson Hotel, Lower Level

8:00am-8:30am
Registration and Breakfast

8:30am-8:35am
Opening Remarks: Betsy Herold, MD

Session 1: Avenues to a Cure/ Pathogenesis
Moderators: Betsy Herold, MD & Scott McClelland, MD, MPH

Plenary Presentations

8:35am- 9:05am
Jonathan Karn, PhD
"Estrogen Receptor and sex differences in HIV latency"
Professor & Chairman, Molecular Biology
Director, Center for AIDS Research
Case Western Reserve University

9:05am-9:35 am
Katherine Luzuriaga, MD
"Early Antiretroviral Therapy and HIV Reservoirs in Infants: Implications for Cure"
Professor, Molecular Medicine, Pediatrics and Medicine
Director, UMass Center for Clinical and Translational Science
Vice Provost, Clinical and Translational Research
University of Massachusetts Medical School

9:35am-10:05am
Dan Kuritzkes, MD
"Progress and Challenges in HIV Cure Research"
Professor, Medicine
Brigham and Women’s Hospital, Harvard University

10:05am-10:20am BREAK

10:20am-10:35am
Neil Ari Wijetuna, MS
"Unique DNA Methylation Signatures in HIV-Associated Cervical Cancer and Cervical Intraepithelial Neoplasia"
PhD Candidate, Genetics
Albert Einstein College of Medicine

10:35am-10:50am
Dionna Williams, PhD
"CD14+CD16+ Monocytes from HIV Positive Individuals Have Increased JAM-A and ALCAM and Preferentially Transmigrate Across the BBB"
Postdoctoral Fellow, Molecular and Comparative Pathobiology
Johns Hopkins University, School of Medicine

10:50am-11:05am
Ekaterina Taneva, MS
"Pharmacokinetics and Pharmacodynamics of Tenofovir and Tenofovir Disoproxil Fumarate in the Female Genital Tract"
PhD Candidate, Microbiology & Immunology and Pediatrics
Albert Einstein College of Medicine

11:05am-11:20am
Alison Roxby, MD MSc
"Changes in Vaginal Microbiota and Cytokines in HIV-1-Seronegative Kenyan Women Initiating DMPA"
Assistant Professor, Medicine
University of Washington, School of Medicine

11:20am-12:05pm
Panel discussion to include invited speakers- respond to oral presentations
Lunch-

Tamara Lewis Johnson, M.B.A., M.P.H.
"NIAID and NIH funding opportunities in Women's Health for early stage investigators "
Women's Health and Extramural Program Manager
Office of Extramural Research Policy and Operations (OERPO)
NIAID, NIH, DHHS
Session 2: HIV Prevention
Moderators: Susan Cu-Uvin, MD & Miriam Kempf, PhD

Plenary Presentations
1:00pm-1:45pm
Walid Heneine, PhD
"HIV Prevention by Antiretroviral Prophylaxis: Lessons from Macaque Models"
Team Lead of non-HIV Surveillance, Drug Resistance & Antiretroviral Prophylaxis
Laboratory Branch, Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention

1:45pm -2:30pm
Angela Mushavi, MBChB, Mmed
"Findings of the Interim Review of Option B+ roll-out in a Resource limited setting; Zimbabwe's Experience in Roll-out of Option B+"
National PMTCT and Pediatric HIV Care and Treatment Coordinator
Ministry of Health and Child Care, Zimbabwe

2:30pm-3:15pm
Shannon Weber, MSW
"Prep me, please: What we know and need to know about PrEP & women's health"
Director, National Perinatal HIV Hotline and Bay Area Perinatal AIDS Center
University of California, San Francisco

Abstract Presentations
3:30pm-3:45pm
Charles Cange, BA, MSc, PhD
"Female Sex Workers Building Up Social Capital amidst Social, Economic, and HIV/AIDS Risks in Burkina Faso”
Postdoctoral Fellow, Center for Public Health and Human Rights
Johns Hopkins University, School of Public Health

3:45pm-4:00pm
Allison M McFall, MHS
"Out of sight, out of mind: High HIV prevalence and low utilization of HIV prevention services among female injection drug users"
Data Analyst, Epidemiology
Johns Hopkins University, Bloomberg School of Public Health

4:00pm-4:15pm
Lakshmi Goparaju, PhD
"Anxiety vs Experience: Differences between HIV- and HIV+ women's opinions on PrEP”
Assistant Professor, Department of Medicine
Project Director, Women's Interagency HIV Study (WIHS)
Georgetown University Medical Center

4:15pm-4:30pm
Julia Raifman, BA, MS
"Preventing HIV Transmission and Unintended Pregnancy: The HIV Treatment Cascade and Contraceptive Choices”
PhD Candidate, Global Health and Population
Harvard University, School of Public Health

3:15pm-3:30pm BREAK

5:30pm-7:00pm Poster session and networking event

Anna Hotton, MPH, PhD
"The VACS Index and gender-related risk factors predict hospitalizations among HIV-infected women”
Epidemiologist
The CORE Center, Cook County Health and Hospitals System

Mimi Ghosh, PhD, MS
"Altered levels of soluble immune mediators in HIV-negative postmenopausal women: Implications for HIV acquisition in the elderly”
Assistant Professor, Epidemiology and Biostatistics
Milken Institute School of Public Health, George Washington University

Radiana Trifonova, PhD
"Myeloid cell subsets in the human cervix and the role of HIV replication in mucosal”
Research Fellow, Pediatrics
Boston Children’s Hospital

Grace Hancock
"Extracellular vesicles and RNA of the cervicovaginal compartment in health and HIV infection”
Laboratory Intern, Molecular and Comparative Pathobiology
Johns Hopkins University

7:00pm-8:00pm Dinner
Main Floor, NoMa Social Restaurant
Session 3: Clinical Disease and Co-morbidities  
Moderator: Kathryn Anastos, MD & Tanvir Bell, MD

Plenary Presentations

8:30am-9:00am
Jennifer Smith, PhD, MPH  
"HPV and Cervical cancer prevention in HIV-seropositive women"  
Associate Professor of Epidemiology  
University of North Carolina, Gillings School of Global Public Health

9:00am-9:30am
Netanya Sandler Utay, MD  
"Inflammation and Non-Communicable Diseases: Causes and Consequences"  
Assistant Professor, Internal Medicine  
University of Texas Medical Branch at Galveston

9:30am-10:00am
Serena Spudich, MD, MA  
"NeuroHIV and Women: What we know and what we need to learn"  
Associate Professor, Neurology  
Chief, Division of Neurological Infections and Global Neurology  
Yale University

10:00am-10:30am
Michael Yin, MD, MS  
"Bone and musculoskeletal disease"  
Associate Professor, Clinical Medicine  
Associate Program Director, Division of Infectious Diseases  
Columbia University Medical Center

Break

Abstract Presentations

10:45am-11:00am
Kerry Murphy, MD  
"Genital Tract HIV Shedding & Mucosal Immunity in Rwandan Women Using Progesterone Contraception"  
Instructor, Medicine  
Albert Einstein College of Medicine

11:00am-11:15am
Erica Hardy, MD, MMSc  
"Impact of Treatment for Trichomoniasis on Genital Tract Inflammatory Mediators Among HIV-Infected Females in South Africa"  
Physician, Medicine and Pediatrics  
Women & Infants Hospital of Rhode Island

11:15am-11:30am
Anjali Sharma, MD, MS  
"Fracture incidence is increased in aging HIV-infected women"  
Associate Professor, General Internal Medicine  
Albert Einstein College of Medicine

11:30am-11:45am
Sylvia LaCourse, MD  
"Active Tuberculosis Screening and Prevalence Among HIV-infected Pregnant Women in Western Kenya"  
Senior Research Fellow  
University of Washington, School of Medicine

Panel discussion to include invited speakers- respond to oral presentations

12:30pm-12:45pm  LUNCH- (pick up box lunches)

12:45pm-1:05pm  LUNCH

12:45pm-1:05pm
Cynthia Grossman, PhD  
"Social and ethical aspects of HIV cure research"  
Chief, HIV Care Engagement and Secondary Prevention Program  
Division of AIDS Research, NIMH

1:05pm-2:15pm  Group Discussion

2:15pm-2:20pm
Closing Remarks: Kathryn Anastos, MD
### Poster Session Program
Monday, December 8th, 5:30-7:00PM

#### Avenues to a Cure/ Pathogenesis

<table>
<thead>
<tr>
<th>#</th>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Michael Dapp, PhD</td>
<td>Viral Evolution in HIV-1 Infected Women: Study of the WIHS Cohort</td>
<td>University of Washington</td>
</tr>
<tr>
<td>2</td>
<td>Jeong Hyun Lee, BS</td>
<td>Rapid structure based epitope mapping of novel broadly neutralizing antibodies</td>
<td>The Scripps Research Institute</td>
</tr>
<tr>
<td>3</td>
<td>Athie Tsibris, MD, MS</td>
<td>HIV-1 Reservoir Size and Antiretroviral Drug Concentrations in the Female Reproductive Tract</td>
<td>Brigham and Women’s Hospital, Harvard Medical School</td>
</tr>
<tr>
<td>4</td>
<td>Roshni Biswas, MBBS, MPHc</td>
<td>Biomarkers in the reproductive tract of sexually active and inactive adolescent girls: implications for HIV susceptibility</td>
<td>Milken Institute School of Public Health, The George Washington University</td>
</tr>
<tr>
<td>5</td>
<td>Mimi Ghosh, PhD</td>
<td>Altered levels of soluble immune mediators in HIV-negative postmenopausal women: Implications for HIV acquisition in the elderly</td>
<td>George Washington University</td>
</tr>
<tr>
<td>6</td>
<td>Grace Hancock</td>
<td>Extracellular vesicles and RNA of the cervicovaginal compartment in health and HIV infection</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>7</td>
<td>Radiana Trifonova, MD, PhD</td>
<td>Myeloid cell subsets in the human cervix and the role of HIV replication in mucosal macrophages and dendritic cells</td>
<td>Boston Children’s Hospital</td>
</tr>
<tr>
<td>8</td>
<td>Rebecca Pellett Madan, MD, MS</td>
<td>Early HIV infection in young women is associated with reduced anti-HSV-2 activity in genital secretions and asymptomatic bacterial vaginosis</td>
<td>Albert Einstein College of Medicine</td>
</tr>
</tbody>
</table>

#### HIV Prevention

<table>
<thead>
<tr>
<th>#</th>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Rosy Chhabra, PsyD</td>
<td>Generation at risk! Need for HIV testing, treatment and preventive interventions to reach girls in low income countries.</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>10</td>
<td>Amanda Gabster, MSc, BSc</td>
<td>Women’s increased risk for HIV infection in Panama: a secondary analysis of the 2009 National Survey on Sexual and Reproductive</td>
<td>Gorgas Memorial Institute for Health Studies</td>
</tr>
<tr>
<td>11</td>
<td>Nadia Nguyen</td>
<td>The association of timing and duration of lifetime physical and sexual trauma with HIV infection among African American women in</td>
<td>University of North Carolina</td>
</tr>
<tr>
<td>12</td>
<td>Amanda Noska, MD, MPH</td>
<td>Factors Associated with Sex Exchange Among Incarcerated Young Women in Providence, RI</td>
<td>Brown University and Lifespan Hospitals</td>
</tr>
<tr>
<td>13</td>
<td>Amy Smoyer, MSW, PhD</td>
<td>Apathy, Nonsense, and Disgust: How women’s experiences with prison food may impact their appetite for HIV care and prevention</td>
<td>Yale School of Public Health</td>
</tr>
<tr>
<td>14</td>
<td>Anne Teitelman, MSN, PhD, RN</td>
<td>Can brain imaging be used to predict known risk factors for HIV infection in young women?</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>15</td>
<td>Yukiko Washio, PhD</td>
<td>Literature Review on the Impact of Substance Use and Intimate Partner Violence on HIV Testing Behavior among Women</td>
<td>Treatment Research Institute</td>
</tr>
<tr>
<td>16</td>
<td>Rongbing Xie, MPH</td>
<td>Modeling Depression Treatment Strategies for Human Immunodeficiency Virus Infected (HIV+) Women Using Agent-based Modeling</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>No.</td>
<td>Name</td>
<td>Title</td>
<td>Institution</td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>17</td>
<td>Alfredo Aguirre</td>
<td>Persistent low-level viremia and virologic failure among a cohort of HIV-infected women on antiretroviral therapy</td>
<td>Emory University</td>
</tr>
<tr>
<td>18</td>
<td>Anna Hotton, MPH, PhD</td>
<td>The VACS Index and gender-related risk factors predict hospitalizations among HIV-infected women</td>
<td>The CORE Center, Cook County Health and Hospitals System</td>
</tr>
<tr>
<td>19</td>
<td>Mark Kuniholm, PhD</td>
<td>Association of Chronic Hepatitis C Infection with T-Cell Phenotypes in HIV-Negative and HIV-Positive Women</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>20</td>
<td>Julian Adong, MBCHB</td>
<td>Prevalence and correlates of depressive symptoms amongst Pre-ART patients in In South Western Uganda.</td>
<td>Mbarara University of Science and Technology</td>
</tr>
<tr>
<td>21</td>
<td>Julie Zuniga, MSN, PhD, RN</td>
<td>Predictors of Glucose Control in Women with HIV and Diabetes</td>
<td>Emory University</td>
</tr>
<tr>
<td>22</td>
<td>Sara Looby, PhD, ANP-BC, FAAN</td>
<td>Longitudinal Assessment of Menopause Symptoms in Perimenopausal Women with HIV</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>23</td>
<td>Karla Maguire, MD</td>
<td>HIV-Positive Women over Age 65: A Growing Population</td>
<td>University of Miami, Miller School of Medicine</td>
</tr>
<tr>
<td>24</td>
<td>Crystal Chapman Lambert, PhD, RN, CRNP</td>
<td>Positive Women’s Beliefs about Cervical Cancer and HPV</td>
<td>The University of Alabama at Birmingham</td>
</tr>
<tr>
<td>25</td>
<td>May Maloba, RN, MCHD</td>
<td>Demographic and clinical characteristics associated with timely utilization of cervical cancer prevention services for women enr</td>
<td>Kenya Medical Research Institute (KEMRI)/Family AIDS Care and Education Services (FACES)</td>
</tr>
<tr>
<td>26</td>
<td>Stephanie Blankenship, MS</td>
<td>Knowledge and Acceptability of Anal Cytology Screening</td>
<td>University of Miami Miller School of Medicine</td>
</tr>
<tr>
<td>27</td>
<td>Florence Momplaisir, MD, MSHP</td>
<td>HIV Care Engagement among Postpartum Women in Philadelphia, 2005-2011</td>
<td>Drexel College of Medicine</td>
</tr>
<tr>
<td>28</td>
<td>Diane Morse, MD</td>
<td>A gender, trauma, and motivationally-based intervention to improve HIV and Hepatitis C healthcare among women drug court partici</td>
<td>University of Rochester School of Medicine</td>
</tr>
</tbody>
</table>
Plenary Speaker Biographies

Dr. Jonathan Karn, "Estrogen Receptor and sex differences in HIV latency"
Professor & Chairman of Molecular Biology
Director, Center for AIDS Research
Case Western Reserve University

HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Our research focuses on defining the molecular basis for HIV silencing, the signaling pathways used to reactivate latent HIV, the impact of drugs of abuse on the creation and reactivation of the latent viral reservoir in microglial cells, and the development of novel therapeutic approaches to attacking HIV latency. Key questions about HIV silencing that remain to be answered include: What are the primary sequence triggers and mechanisms that induce silencing (i.e. protein repressors and/or viral-derived RNA)? What cellular pre-conditions lead to proviral silencing? Do similar silencing mechanisms operate in each of the cell types infected by HIV? How do drugs of abuse reactivate HIV? In partial answer to these questions we have demonstrated that distinct epigenetic silencing mechanisms lead to viral persistence in different cell types. Using novel unbiased shRNA screens we have shown that in T-cells, the polycomb repressive complex 2 (PCRC2) plays a central role in maintaining proviral latency, whereas in microglial cells, PCRC2 is absent and silencing is mediated by the SMRT and CoREST silencing machinery. Because of these differences in the silencing machinery we have been able to identify selective activators of HIV transcription in the two different cell types. Extending this work we plan to develop novel technologies allowing exploitation a natural epigenetic silencing mechanisms involving both histone and DNA methylation, to block HIV transcription. Our laboratory has developed an extensive network of collaborations with academic and pharmaceutical partners as part of our work on HIV eradication. Our laboratory is a participant in the Martin Delaney Collaboratory of AIDS Researchers for Eradication (CARE), a network of twenty leading laboratories working on HIV eradication strategies, the amfAR Research Consortium on HIV Eradication (ARCH), the HIV Reservoirs and Viral Eradication Transformative Science Group (TSG) of the AIDS Clinical Trials Group (ACTG) and we are also working in close collaboration with Merck on identification of novel HIV therapeutics.

Dr. Katherine Luzuriaga, "Early Antiretroviral Therapy and HIV Reservoirs in Infants: Implications for Cure"
Professor, Molecular Medicine, Pediatrics and Medicine
Director, UMass Center for Clinical and Translational Science
Vice Provost, Clinical and Translational Research
University of Massachusetts Medical School

Dr. Luzuriaga is Professor of Molecular Medicine, Pediatrics, and Medicine; Director of the UMass Center for Clinical and Translational Science (UMCCTS); and Vice Provost for Clinical and Translational Research at the University of Massachusetts Medical School. As a physician-scientist, her research, focused on understanding viral and host factors that result in persistent viral (HIV, EBV, CMV) infections in children, has provided multiple insights relevant to HIV cure, including the genetic and biologic characterization of variants that are transmitted from women to their infants, the dynamics of early viral replication and HIV reservoir formation in infants, the ontogeny of HIV-1 specific immune responses in HIV-infected infants, and defining the role of HIV-1 specific CD8+ T cells in controlling viral replication or evolution of the HIV quasispecies. She has also been active in translational research that helped to define the timing of mother-to-child HIV transmission, led to the pediatric labeling of multiple antiretrovirals (including nevirapine), and she led the first early therapy trials in infants. Her research has been supported over the years by RO1 and P01 funding from the National Institutes of Health, the Charles Hood Foundation, the Elizabeth Glaser Pediatric AIDS Foundation, and the American Foundation for AIDS Research (Amfar). Dr. Luzuriaga has held several leadership positions within the US National Institutes of Health-sponsored Pediatric AIDS Clinical Trials and IMPAACT Groups, and currently serves on the NIH NCATS-CTSA Steering Committee. She has served as a consultant to the World Health Organization, as a member of the Institute of Medicine’s Committee on the Perinatal Transmission of HIV, and as a member of the NIH Office of AIDS Research Etiology and Pathogenesis Planning Committee. Dr. Luzuriaga is a recipient of a Scholar Award and an Elizabeth Glaser Scientist Award from the Elizabeth Glaser Pediatric AIDS Foundation. Named to the 2013 TIME 100 Most Influential People in the World and the 2013 Foreign Policy Global Thinkers lists, Dr. Luzuriaga is particularly interested in communicating to policy makers and the public the importance of scientific investigation for improving health.
Dr. Dan Kuritzkes, "Progress and Challenges in HIV Cure Research"
Professor of Medicine
Brigham and Women's Hospital, Harvard University

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and is a member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has served on numerous NIH committees and editorial boards, and previously served as Chair of the HIV Medicine Association Board of Directors. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group, and as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.

Dr. Walid Heneine, "HIV Prevention by Antiretroviral Prophylaxis: Lessons from Macaque Models"
Team Lead of Surveillance of non-HIV Surveillance, Drug Resistance, Antiretroviral Prophylaxis
Laboratory Branch, Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention

Walid Heneine is currently the Team Lead of Surveillance, Antiretroviral Prophylaxis, Drug Resistance, at the Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention. His research focuses on evaluating the efficacy of antiretroviral prophylaxis for HIV prevention using monkey models of rectal and vaginal transmission and identifying effective modalities that can inform clinical trial designs for systemic and topical prophylaxis. His lab also works on HIV drug resistance with a focus on transmitted drug resistance, its prevalence, virology, and persistence, and development of sensitive technologies for detecting minority resistance and assessing its clinical implications. Dr. Heneine’s lab also investigates the emergence and impact of new retroviruses and reported the discovery in humans of three novel retroviruses, the simian foamy viruses, and the human T lymphotropic viruses types 3 and 4.
Dr. Angela Mushavi, "Findings of the Interim Review of Option B+ roll-out in a Resource limited setting; Zimbabwe's Experience in Roll-out of Option B+"
National PMTCT and Pediatric HIV Care and Treatment Coordinator,
Ministry of Health and Child Care, Zimbabwe

Angela Mushavi is a pediatrician with a strong passion to see new HIV infections in children averted, and children affected by HIV receiving the care and treatment they require and living healthy, quality lives. Currently working in the Ministry of Health and Child Care in Zimbabwe as the National PMTCT and Pediatric HIV Care and Treatment Coordinator, she has over 18 years working in HIV and AIDS programming in Zimbabwe and in Namibia where she worked as a PMTCT Technical Advisor with CDC supporting the Ministry of Health and Social Services. She has hands on clinical experience of managing and treating children living with HIV, having worked in a Paediatric ART clinic in Windhoek and been a pediatric consultant at Harare Children’s Hospital before that.

Angela Mushavi has worked in the areas of PMTCT and Pediatric HIV policy formulation and guideline development, and has presented on PMTCT and Pediatric HIV at national, regional and international conferences. She has clinical and programmatic experience of running PMTCT and pediatric HIV services and has contributed to the design and implementation of operational research and training curricula that supports expansion of national PMTCT and Pediatric HIV and AIDS care and treatment programs.

A strong advocate for children, she is a steering committee member of the African Network for the Care of Children Affected by HIV (ANECCA) which strongly advocates for the care, treatment and support of children affected by HIV, and the integration of HIV and MNCH services

Ms. Shannon Weber, "Prep me, please: What we know and need to know about PrEP & women’s health"
Director of National Perinatal HIV Hotline and Bay Area Perinatal AIDS Center
Assistant Faculty of San Francisco Department of Public Health
University of California, San Francisco

Shannon Weber, MSW is the Director of UCSF’s National Perinatal HIV Hotline, a free 24/7, expert consultation service and the Bay Area Perinatal AIDS Center (BAPAC), a San Francisco General Hospital (SFGH) program providing preconception and prenatal care to HIV-affected individuals. Shannon launched the PRO Men (Positive Reproductive Outcomes for HIV+ Men) initiative, an innovative collaboration between BAPAC and SFGH’s Ward 86 HIV Clinic integrating men’s reproductive and sexual health care into a primary care setting. She is faculty with the San Francisco Department of Public Health’s Capacity Building Assistance program.
Dr. Netanya Sandler Utay, "Inflammation and Non-Communicable Diseases: Causes and Consequences"
Assistant Professor of Internal Medicine
University of Texas Medical Branch at Galveston

Dr. Netanya Sandler Utay completed her undergraduate degree in Molecular Biophysics and Biochemistry at Yale University in 1998. Her research interest was piqued while working on the human genome project during the summers and performing her senior research project in the laboratory of Nobel laureate Dr. Thomas Steitz. She attended medical school at Baylor College of Medicine, during which time she spent one year as a Howard Hughes Medical Institute-National Institutes of Health Research Scholar. At the NIH, she became interested in the study of host-pathogens interactions, focusing on fibrotic mediators in a mouse model of schistosomiasis in Dr. Thomas Wynn’s laboratory. After completing medical school, she ventured to the University of Washington for residency in internal medicine and then returned to the NIH for infectious diseases fellowship.

Dr. Utay (then called Sandler) spent 5.5 years working with Dr. Daniel Douek, investigating the causes and consequences of inflammation in HIV infection. During this time, she formed many collaborations and performed numerous exploratory interventional studies in the SIV rhesus macaque model. She proceeded to co-chair 2 studies with the AIDS Clinical Trials Group. Her work at the NIH resulted in first author publications in the Journal of Infectious Diseases, Gastroenterology, and Nature, hopefully with more publications to come. In 2013, she joined faculty at the University of Texas Medical Branch at Galveston in the Department of Internal Medicine, Division of Infectious Diseases, where she is pursuing a career as a physician-scientist. She maintains HIV and HCV continuity clinics, runs a laboratory, and continues to co-chair studies locally and with the ACTG. In her free time, she enjoys maintaining her 1-acre yard with her husband, cooking, and enviously watching her dog sleep.

Dr. Jennifer Smith, "HPV and Cervical cancer prevention in HIV-seropositive women"
Associate Professor of Epidemiology
University of North Carolina, Gillings School of Global Public Health

Dr. Jennifer S. Smith’s current research focuses on epidemiological studies of cervical cancer and human papillomavirus (HPV) infections worldwide, with a focus on reproductive health, and infections and cancer prevention. Dr. Smith is an Associate Professor in the Department of Epidemiology at the UNC Gillings School of Global Public Health. She is also affiliated with the UNC Lineberger Comprehensive Cancer Center (Cancer Epidemiology), UNC Center for AIDS Research, and the UNC Center for Women’s Health Research. She has conducted research on HPV and associated cervical neoplasia and cancer since 1995. Dr. Smith has published over 200 articles in international peer-reviewed journals, of which over 170 are related to HPV infection and HPV-associated diseases, including cervical, anal, vaginal, vulvar and penile cancers. She is the Director of the Cervical Cancer-Free Coalition, a global initiative to reduce cervical cancer. She is the Principal Investigator (PI) of a cohort of female sexual workers in Nairobi, Kenya, and recently as the PI on a NCI R01 study, the Effect of Male Circumcision on the Natural History of Penile HPV Infection in Kisumu, Kenya. Her current research focuses on epidemiological studies of HPV and cervical cancer worldwide (primarily in North Carolina, China, Kenya and South Africa), with a focus on prevention via screening and prophylactic vaccines.

Dr. Serena Spudich, "NeuroHIV and Women: What we know and what we need to learn"
Associate Professor of Neurology
Chief, Division of Neurological Infections and Global Neurology
Yale University

Dr. Spudich graduated from medical school at the University of California, San Francisco (UCSF) in 1997, then pursued residency at the University of Washington in Internal Medicine and at the Harvard Massachusetts General Hospital/Brigham and Women’s Hospital program in Neurology. She returned to UCSF in as a fellow in NeuroHIV, remaining at UCSF as faculty until moving to Yale in 2010. Through clinical studies in urban US centers and in Bangkok, Thailand, she has explored the pathogenesis of HIV in the nervous system, focusing on establishment and maintenance of HIV reservoirs in the brain. She is active in the AIDS Clinical Trials Group as Vice-Chair of the Neurology committee and a member of the Cure committee. Finally, Dr. Spudich cares for for HIV-infected patients with neurological disorders at the Nathan Smith HIV Clinic at Yale.
Dr. Michael Yin, "Bone and musculoskeletal disease"
Associate Professor of Clinical Medicine
Associate Program Director in the Division of Infectious Diseases
Columbia University Medical Center

Dr. Yin is an Associate Professor of Medicine in the Division of Infectious Diseases. His primary research focus is on the metabolic complications of HIV infection and antiretroviral therapy. He is the Principal Investigator of a NIAID-funded R01 to examine the effects of the menopausal transition on bone and muscle outcomes in HIV-infected women in the Women’s Interagency HIV study (WIHS), utilizing imaging and biomarker techniques, novel in vitro bone precursor cell assays and assessment of muscle mass, quality and functional performance. He is the Co-Principal Investigator of a NICHD-funded R01 to examine bone health in perinatally HIV-infected children on antiretrovirals in South Africa. As a member of the Bone and Metabolic Working Groups for the WIHS, Veterans Aging Cohort Study (VACS) and AIDS Clinical Trials Group (ACTG), Dr. Yin is involved in other studies on bone, fracture, and other metabolic complications in HIV-infected individuals. He is the Co-Chair of ACTG 5280, a study to evaluate whether high dose vitamin D supplementation mitigates the bone loss associated with initiation of antiretroviral therapy in HIV-infected individuals. He is also a site investigator for the HIV Vaccine Trials Network (HVTN) and is Chair of HVTN 404 and Co-chair of HVTN 505.
Metro North Directions from Grand Central to Radisson in New Rochelle

6:41 AM–7:21 AM (40 min)
- 6:41 AM: Grand Central Terminal
  69 E 42nd St, New York, NY 10017
- 6:41 AM: Grand Central
- 7:13 AM: New Rochelle
  Walk to Radisson Hotel New Rochelle
  About 8 min, 0.4 mi
- 7:21 AM: Radisson Hotel New Rochelle
  One Radisson Plaza, New Rochelle, NY 10801

Walking Directions from New Rochelle Amtrak to Radisson in New Rochelle

Walk 0.4 mile, 8 min
Use caution - may involve errors or sections not suited for walking

Amtrak Station NRO
1 Railroad Ave, New Rochelle, NY 10801
1. Head northeast on Railroad Ave toward Bridge St 121 ft
2. Turn right onto Bridge St 225 ft
3. Turn left onto Huguenot St 0.3 mi
4. Turn left onto Cedar St 332 ft
5. Turn right onto Radisson Plaza 104 ft

Radisson Hotel New Rochelle
One Radisson Plaza, New Rochelle, NY 10801

These directions are for planning purposes only. You may find that construction projects, traffic, weather, or other events may cause conditions to differ from the map results, and you should plan your route accordingly. You must obey all signs or notices regarding your route.
Driving Directions from LaGuardia Airport to the Radisson Hotel in New Rochelle

Drive 14.8 miles, 20 min

1. LaGuardia Airport
   New York 11371
   - Take I-678 N, Hutchinson River Pkwy N and I-95 N to Garden St in New Rochelle. Take exit 16 from I-95 N  
     14.5 mi / 19 min
   - Take Cedar St to Radisson Plaza  
     0.3 mi / 50 s
   - Turn left onto Garden St  
     400 ft
   - Take the 1st right onto Cedar St  
     0.2 mi
   - Turn left onto Radisson Plaza  
     Destination will be on the right  
     184 ft

Radisson Hotel New Rochelle
One Radisson Plaza, New Rochelle, NY 10801

Driving Direction from JFK Airport to the Radisson Hotel in New Rochelle

Drive 22.9 miles, 34 min

1. JFK Airport, Jamaica, NY
   - Continue to Van Wyck Expy  
     0.6 mi / 3 min
   - Take I-678 N to Van Wyck Blvd. Take the exit toward Rockaway Blvd from I-678 N  
     3.0 mi / 4 min
   - Get on I-678 N  
     1.8 mi / 4 min
   - Follow I-678 N, Hutchinson River Pkwy N and I-95 N to Garden St in New Rochelle. Take exit 16 from I-95 N  
     17.6 mi / 23 min
   - Take Cedar St to Radisson Plaza  
     0.3 mi / 50 s
   - Turn left onto Garden St  
     400 ft
   - Take the 1st right onto Cedar St  
     0.2 mi
   - Turn left onto Radisson Plaza  
     Destination will be on the right  
     184 ft

Radisson Hotel New Rochelle
One Radisson Plaza, New Rochelle, NY 10801
Driving Directions from Newark Airport to the Radisson Hotel in New Rochelle

Drive 37.1 miles, 48 min

▲ This route has tolls.

- Newark Liberty International Airport
  3 Brewster Rd, Newark, NJ 07114
  - Get on I-78 E from Newark International Airport St
    - 2.6 mi / 3 min
  - Take I-95 N to Garden St in New Rochelle. Take exit 16 from I-95 N
    - 34.0 mi / 42 min
  - Take Cedar St to Radisson Plaza
    - 0.3 mi / 5 min
  - Turn left onto Garden St
    - 400 ft
  - Take the 1st right onto Cedar St
    - 0.2 mi
  - Turn left onto Radisson Plaza
    - Destination will be on the right

Radisson Hotel New Rochelle
One Radisson Plaza, New Rochelle, NY 10801

MTA Directions from AECOM to the Radisson Hotel in New Rochelle

6.57 AM – 7.48 AM (51 min)

6:57 AM  Albert Einstein College of Medicine
1300 Mott's Park Ave, Bronx, NY 10461
- Walk to Pelham Pkwy/Eastchester Rd
  About 6 min, 0.3 mi

7:03 AM  Pelham Pkwy/Eastchester Rd

7:18 AM  E Fordham Rd/Third Av

7:26 AM  Fordham
- New Canaan towards New Canaan
  14 min (3 stops)

7:40 AM  New Rochelle
- Walk to Radisson Hotel New Rochelle
  About 8 min, 0.4 mi

7:48 AM  Radisson Hotel New Rochelle
One Radisson Plaza, New Rochelle, NY 10801

MTA New York City Transit - 1 718-330-1234  •  Metro-North Railroad - 1 212-662-4900
Driving Directions from AECOM to the Radisson Hotel in New Rochelle

Drive 7.1 miles, 11 min

1. Albert Einstein College of Medicine
   1300 Morris Park Ave, Bronx, NY 10461
   - Get on Hutchinson River Pkwy N from Tenbroeck Ave, Morris Park Ave, Stillwell Ave and Bronx and Pelham Pkwy
     1.4 mi / 4 min
   - Follow Hutchinson River Pkwy N and I-95 N to Garden St in New Rochelle. Take exit 16 from I-95 N
     8.4 mi / 6 min
   - Take Cedar St to Radisson Plaza
     0.3 mi / 5 min
     13. Turn left onto Cedar St
     14. Take the 1st right onto Cedar St
     15. Turn left onto Radisson Plaza
         Destination will be on the right

2. Radisson Hotel New Rochelle
   One Radisson Plaza, New Rochelle, NY 10801
### Car Service Options to Airports:

- **Green Team Taxi**: 914-576-1200
- **Blue Bird Taxi**: 914-632-0909
- **Uber Car Service Phone Application**
- **1st Choice Taxi**: 914-632-8000

### Restaurant Options in New Rochelle:

<table>
<thead>
<tr>
<th>Restaurant</th>
<th>Address</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>NoMa Social</td>
<td>1 Radisson Plaza</td>
<td>914-576-4141</td>
</tr>
<tr>
<td>The Dining Lab at Monroe College</td>
<td>434 Main Street</td>
<td>914-740-6421</td>
</tr>
<tr>
<td>Alvin &amp; Friends</td>
<td>14 Memorial Hwy</td>
<td>914-654-6549</td>
</tr>
<tr>
<td>Texas Roadhouse</td>
<td>181 Huguenot Street</td>
<td>914-632-7427</td>
</tr>
</tbody>
</table>
The Einstein-Montefiore Center for AIDS Research (CFAR) coordinates, stimulates and supports the multidisciplinary research activities of over 120 NIH-funded faculty investigators at the Albert Einstein College of Medicine (Einstein) and Montefiore Medical Center (Montefiore). Our CFAR plays a crucial role in enabling our investigators to uncover new mechanisms by which HIV-1 infects cells and causes disease and to translate these discoveries into new therapies, approaches and interventions to improve the treatment of HIV-1-infected individuals prevent the further spread of HIV-1 infection. This translational research is particularly relevant to members of our community which includes nearly 15,000 HIV-infected men and women infected with HIV-1, more than 90% Latino or African American as well as our affiliated international sites located in areas where HIV infection is endemic.
The Einstein-Montefiore Center for AIDS Research gratefully acknowledges the organization whose generosity and support made this conference possible.

Specifically, we would like to acknowledge the work of the planning and organizing committees.

Planning Committee

Kathryn Anastos, MD
Professor of Medicine, Epidemiology & Population Health and Obstetrics & Gynecology and Women’s Health
Co-director of the Einstein Global Health Center
Albert Einstein College of Medicine

Linda Baum, MD, PhD
Medical Director, Clinical Laboratory
Professor of Pathology & Laboratory Medicine & Hematopathology & Hematology

Tanvir Bell, MD
Associate Professor of Infectious Diseases
University of Texas, Medical Center at Houston

Gina Brown, MD
Medical Office for Women and Girl and HIV/AIDS Research
Chair, Microbicides Coordinating Committee
Microbicides and Women & Girls Research Coordinator
Office of AIDS Research, NIH

Susan Cu-Uvin, MD
Professor of Obstetric and Gynecology and Medicine
Director, Global Health Initiative
Brown University

Vicki Godleski
Executive Administrator CFAR
Lifespan, Tufts, Brown

Ruth Greenblatt, MD
Professor of Clinical Pharmacy
UCSF School of Pharmacy

Betsy Herold, MD
Chief of the Division of Pediatric Infectious Diseases
Professor of Pediatrics, Microbiology & Immunology and Obstetrics & Gynecology
Director, Translational Preventive Research Center
Albert Einstein College of Medicine

Deborah Jones, MEd, PhD
Co-Director of Developmental Core, CFAR
Research Associate Professor of Psychiatry & Behavioral Sciences
University of Miami Miller School of Medicine

Miriam Kempf , PhD
Assistant Professor of Health Behavior
University of Alabama at Birmingham, School of Public Health

Alan Landay, PhD
Professor and Chair of Immunology-Microbiology
Chair , NIH Office of AIDS Research Pathogenesis Panel and National WIHS Pathogenesis Committee
Rush Medical College

Scott McClelland, MD, MPH
Professor of Allergy and Infectious Disease, Epidemiology and Global Health
University of Washington, School of Public Health

Christina Psaros, PhD
Assistant Professor of Psychiatry
Harvard Medical School

Grace John Stewart, MD, MPH, PhD
Professor of Allergy and Infectious Diseases, Epidemiology, Global Health & Pediatrics
University of Washington, School of Public Health

Organizing Committee

Julia Dettinger
University of Washington

Lynn Murchinson
Montefiore Medical Center

Sandra Pinzow
Albert Einstein College of Medicine

Georgia Veroutis
Albert Einstein College of Medicine